A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single and Multiple Doses of PIPE-791 and Food Effect in Normal Healthy Volunteers
Latest Information Update: 19 Feb 2024
At a glance
- Drugs PIPE 791 (Primary)
- Indications Idiopathic pulmonary fibrosis; Multiple sclerosis
- Focus Adverse reactions; First in man
- Sponsors Contineum Therapeutics
Most Recent Events
- 12 Feb 2024 Status changed from recruiting to completed.
- 13 Dec 2023 According to Contineum Therapeutics media release, Pipeline Therapeutics has changed its name to Contineum Therapeutics
- 01 Aug 2023 According to Pipeline Therapeutics media release, the company expects enrollment to be completed by year end 2023.